Patent DE-102008029688-A1 (DE)
Title: Determining and identifying variant of Clostridium difficile strain in sample, comprises obtaining sample, contacting sample with antibody, detecting antibody reaction, comparing obtained reaction pattern with reference and correlating
Inventor: BRAUN VEIT
IPC: G01N33/569
Filed: 2008-06-24
Abstract: Determining and identifying a variant of Clostridium difficilestrain in a sample, comprises: (a) obtaining a body exudate sample and/or body tissue sample; (b) contacting the sample with at least one antibody consisting of antibody groups of group I-VI; (c) detecting the antibody reaction and generating a reaction pattern; (d) comparing the reaction pattern obtained in step (c) with reference pattern; and (e) assessing a correlation between the reaction pattern obtained in step (c) with a reference pattern. Determining and identifying a variant of Clostridium difficilestrain in a sample, comprises: (a) obtaining a body exudate sample and/or body tissue sample; (b) contacting the sample with at least one antibody consisting of antibody groups of group I, group II, group III, group IV, group V or group VI, where group I comprises pan-TcdB antibody, group II comprises antibody that reacts with toxins including TcdB-10463 and TcdB-017 and not with TcdB-8864 and TcdB-027, group III comprises antibody that reacts with TcdB-10463, and not with toxins TcdB-8864, TcdB-017 and TcdB-027, group IV comprises antibody that reacts with toxins TcdB-8864, TcdB-017 and TcdB-027 and not with TcdB-10463, group V comprises antibody that reacts with toxin TcdB-8864 and TcdB-027 and not with toxins TcdB-10463 and TcdB-017, and group VI comprises pan-TcdA antibodies; (c) detecting the antibody reaction and generating a reaction pattern, where in step (b) each of the used antibody of the antibody group I to VI is assigned a positive symbol for a detected positive antibody reaction and a negative symbol for a detected negative antibody reaction; (d) comparing the reaction pattern obtained in step (c) with reference pattern, and in the detection test for the presence of C. difficilestrain Rx 1, Rx 2and Rx ithat are to be screened, at least one of their large clostridial toxins (LCT) LCT-Rx 1, LCT-Rx 2or LCT-Rx iis used in a reaction test with at least three antibody groups I-VI and the reaction results obtained for each LCT and each of the three antibody are registered as patterned zone so that for each antibody group a positive symbol, in the case of a detected positive antibody response, or negative symbol, in the case of a detected negative antibody response, is assigned; and (e) assessing a correlation between the reaction pattern obtained in step (c) with a reference pattern as an indication that the C. difficilestrain is present in the sample. Independent claims are included for: (1) a monoclonal antibody, which is produced from the hybridoma cell line and deposited in the DSMZ, Brunswick, Germany under the number DSM ACC2916 (TGC 19), for use in the above method for detecting and identifying the C. difficilestrain with ribotype 027, PF-GE-NAP 1, REA-B1 and toxinotype III; (2) a monoclonal antibody, which is produced from the hybridoma cell line and deposited in the DSMZ, Brunswick, Germany under the number DSM ACC2917 (TGC 23), for use in the above method for detecting and identifying the C. difficilestrain with ribotype 017, toxinotype VIII and serotype F; (3) a monoclonal antibody, which is produced from the hybridoma cell line and deposited in the DSMZ, Brunswick, Germany under the number DSM ACC2915 (TGC 16), for use in the above method for detecting and identifying the C. difficilestrain with ribotype 017, toxinotype VIII and serotype F and/or ribotype 027, PFGE-NAP 1, REA-B1 and toxinotype III; and (4) a monoclonal antibody, which is produced from the hybridoma cell line and deposited in the DSMZ, Brunswick, Germany under the number DSM ACC2918 (TGC 35), for use in the above method for detecting and identifying the C. difficilestrain with ribotype 017, toxinotype VIII and serotype F and/or ribotype 027, PFGE-NAP1, REA-B1 and toxinotype III.